Skip to main content

Wesley Self Archives

VUMC-led COVID-19 clinical trial platform goes international

Jan. 5, 2023—The ACTIV-4 Host Tissue clinical trial platform, which is designed to investigate therapies targeting the host tissue response to COVID-19 to mitigate lung injury, is now being expanded internationally.

Read more


Bivalent booster vaccine effective in preventing COVID-19 hospitalization in older adults

Dec. 16, 2022—The new bivalent mRNA COVID-19 booster vaccines that began being used in September are beneficial in preventing COVID-19-associated hospitalization in persons 65 and over.

Read more


VUMC Announces VICTR Leadership Transition

Dec. 16, 2022—by Bill Snyder Gordon Bernard, MD, a leader in clinical and translational medicine at Vanderbilt University Medical Center for more than 40 years, will step aside from his institutional leadership roles in July 2023 to focus more on his research interests and allow a new generation of leaders to take center stage. Bernard, the Melinda...

Read more


Self named co-principal investigator of Vanderbilt’s Clinical and Translational Science Award

Sep. 22, 2022—Wesley Self, MD, MPH, a physician-scientist at Vanderbilt University Medical Center, has been named co-principal investigator (co-PI) of Vanderbilt’s Clinical and Translational Science Award (CTSA).  

Read more


Convalescent plasma doesn’t help severely ill COVID patients: study

Jul. 7, 2022—A Vanderbilt clinical trial shows that convalescent plasma, widely given to severely ill patients hospitalized with COVID-19 during the pandemic, does not improve their ability to survive or recover

Read more


Additional COVID vaccine helps protect transplant patients

Apr. 13, 2022—Additional booster doses of vaccine against COVID-19 are particularly important for those who are immunosuppressed, namely those who have had solid organ transplants, a new study shows.

Read more


Vanderbilt and CDC research shows third vaccine dose key to preventing omicron hospitalization

Feb. 9, 2022—Vanderbilt research shows that two doses of an mRNA COVID-19 vaccine result in lower effectiveness for preventing hospitalization for the omicron variant than previous variants. However, importantly, a third (“booster”) vaccine dose significantly improves protection against omicron hospitalization up to 86%.

Read more


Grant boosts vaccine effectiveness research

Jan. 6, 2022—by Nancy Humphrey Investigators at Vanderbilt University Medical Center have received a $10.7 million research award from the Centers for Disease Control and Prevention (CDC) to continue the IVY Research Network, originally created in 2019 to look at how well flu vaccines work at preventing severe flu illness, and expanded in 2021 to enroll patients...

Read more


VUMC, NIH launch clinical trial to test novel therapies to protect host tissue against COVID-19

Jul. 26, 2021—Vanderbilt University Medical Center researchers, supported by the National Institutes of Health (NIH), are leading a nationwide clinical trial to explore the safety and effectiveness of a group of novel drugs designed to protect patients hospitalized with COVID-19 at high risk of poor outcomes.

Read more


Study to evaluate effectiveness of COVID-19 vaccines in preventing hospitalization

Mar. 2, 2021—As the Federal Drug Administration (FDA) considers adding a third COVID-19 vaccine to the rollout, a multicenter study led by Vanderbilt University Medical Center will evaluate how effective the vaccines are in preventing hospitalization from COVID-19.

Read more


Convalescent plasma improved survival in COVID-19 patients with blood cancers

Feb. 5, 2021—Treatment with convalescent plasma vastly improved the survival rate of patients hospitalized for COVID-19 who also had hematologic malignances that compromise the immune system, according to new data released by the COVID-19 and Cancer Consortium (CCC19).

Read more


Hydroxychloroquine does not help patients hospitalized with COVID-19: Study

Nov. 9, 2020—Findings from a national study published Nov. 9 in the Journal of the American Medical Association (JAMA) “do not support” the use of hydroxychloroquine for the treatment of adult patients hospitalized with COVID-19, the report concludes.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more